featured-image

( MENAFN - PR Newswire) REDMOND, Wash., May 23, 2024 /PRNewswire/ -- SystImmune, Inc., a pioneering clinical-stage biopharmaceutical company focused on developing novel therapeutic bi-specific, multi-specific antibodies, and antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the appointment of Dr.

Jonathan Cheng as Chief Medical Officer. He joined SystImmune from Bristol Myers Squibb, where he served as the Senior Vice President and Therapeutic Area Oncology Head, overseeing late-stage clinical development of the oncology portfolio. Dr.



Cheng succeeds Dr. Martin Olivo, who is leaving SystImmune to pursue external opportunities. "I am excited to welcome Dr.

Cheng to our leadership team," said Jie D'Elia, Ph.D., Chief Executive Officer of SystImmune.

"His global oncology development expertise and in-depth regulatory knowledge will accelerate our efforts to advance SystImmune's pipeline and transform patient care. On behalf of the SystImmune team, I want to express our deep appreciation to Dr. Martin Olivo for his dedication and contributions to SystImmune.

We wish him well in his future endeavors." Dr. Yi Zhu, Chairman of SystImmune, stated "Dr.

Cheng brings a wealth of expertise and a remarkable track record in oncology drug development, making him an invaluable addition to SystImmune's executive leadership team." Dr. Cheng's career spans both the pharmaceutical industry and academia, where he has consistently demonstrated exceptional leadership and a.

Back to Health Page